Aurinia Pharmaceuticals (NASDAQ:AUPH) has had a rough three months with its share price down 10%. But if you pay ...

In this article, we are going to take a look at where Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) stands against other stocks that are receiving the most insider investment in March.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Total Revenue (Q4 2024): $59.9 million, up 33% from $45.1 million in Q4 2023. Total Revenue (Full Year 2024): $235.1 million, up 34% from $175.5 million in 2023. Net Product Sales of LUPKYNIS (Q4 ...

EDMONTON, Alberta (AP) — EDMONTON, Alberta (AP) — Aurinia Pharmaceuticals Inc. (AUPH) on Thursday reported fourth-quarter net income of $1.4 million, after reporting a loss in the same period a year ...

The annual results for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) were released last week, making it a good time to revisit its performance. It looks like a credible result overall - although revenues ...

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.19 per share a year ago. These ...

One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. To get the accrual ratio we first subtract FCF from profit for a period, ...

Stocks Leading in March. In this article, we are going to take a look at where Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ...

ROCKVILLE, Md. & EDMONTON, Alberta, February 20, 2025--Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025 Corcept (CORT) ...

Total Revenue (Q4 2024): $59.9 million, up 33% from $45.1 million in Q4 2023. Total Revenue (Full Year 2024): $235.1 million, up 34% from $175.5 million in 2023. Net Product Sales of LUPKYNIS (Q4 2024 ...